Digestery
Longevity supplements › Metformin and Aging › Studies

Randomized trial · measured other health measures

Trial in 1830 adults at diabetes risk: no clear change in walking on metformin

Munshi and colleagues · Frontiers in public health · 2024

Original title: Long-term impact of Diabetes Prevention Program interventions on walking endurance.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

No difference

Neither intervention changed test completion or distance walked: 362, 364, and 360 m in the lifestyle, metformin, and placebo groups (p = 0.8).

The study at a glance

Type of study
Randomized trial
Who or what was studied
1,830 people · Adults at high risk of type 2 diabetes (not yet diabetic at start), tested for walking 20 years later
What was tested
Metformin or intense lifestyle program vs placebo for 3 years, then follow-up; 6-minute walk test at 20 years
What it measured
Other health or performance measures
Trial registration
NCT00038727, NCT00004992
Who has a stake
Company stake
Authors report consulting for Sanofi and Merck KGaA, which supplies metformin; others work or worked for Novo Nordisk and Amgen.
Journal
Frontiers in public health, 2024
Source
PubMed record 39744353. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • ✓Large: 1,830 people.
  • •Measured other health measures, not aging, frailty and death in people without diabetes itself.
  • –Company stake: Authors report consulting for Sanofi and Merck KGaA, which supplies metformin; others work or worked for Novo Nordisk and Amgen.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related disease

    1

    1 benefit

  2. Trials in people: other measures

    3

    2 no difference, 1 harm

    ↑ This study is the ringed dot

  3. Trials in people: lab tests or safety

    6

    2 benefit, 2 mixed, 2 no difference

  4. Population studies

    8

    6 benefit, 2 no difference

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    3

    2 benefit, 1 harm

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does metformin slow aging in people without diabetes?”

Not shown in people without diabetes.

Confidence: low. Based on 26 on-topic papers.

Read the full answer

Of the other 2 papers on the same step: 1 no difference, 1 harm. This one found no difference.

  • Quoted in “What we found”: Twenty years after a trial in 1830 people at high risk of diabetes, the metformin and placebo groups walked similar distances in 6 minutes: 364 m and 360 m.
  • Part of the finding “Trials of walking and frailty found no benefit”.

Other papers on the same step

See all 26 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.